Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Concordix is a health technology company specializing in a patented oral delivery system known as the "Smart Chew." As a business unit of Ayanda and Aker BioMarine, Concordix provides a unique gel matrix platform that allows for high-dosage delivery of active ingredients like Omega-3 fatty acids and vitamins with enhanced bioavailability. The technology is designed to overcome the limitations of traditional delivery forms like softgels and gummies by offering a sugar-free, high-payload, and easy-to-swallow format. Concordix operates as a contract development and manufacturing organization (CDMO), collaborating with global healthcare and supplement brands to bring innovative products to market. Their manufacturing facilities in Germany are GMP-certified, ensuring high-quality production for the pharmaceutical and nutraceutical industries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Concordix.